Soleno Therapeutics (SLNO) Net Cash Flow (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Net Cash Flow of $62.9 million for Q1 2026, up 1053.77% year-over-year from $5.5 million in Q1 2025, and up 135.64% quarter-over-quarter from -$176.6 million in Q4 2025.
Soleno Therapeutics (SLNO) Net Cash Flow (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Net Cash Flow for 14 consecutive years, with $62.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 1053.77% year-over-year to $62.9 million; the TTM figure through Mar 2026 stood at $51.7 million (up 34.33% YoY), while the FY2025 annual figure was -$17.8 million, up 78.2% from the prior year.
- Net Cash Flow grew to $62.9 million in Q1 2026 per SLNO's latest filing, from -$176.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $170.2 million in Q3 2025 and bottomed at -$176.6 million in Q4 2025.
- Historically, Net Cash Flow has averaged $6.6 million across 5 years, with a median of -$4.3 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow jumped 2377.02% — and 2024, when it plunged 1785.17%.
- Soleno Therapeutics' Net Cash Flow stood at -$5.1 million in 2022, then surged by 2377.02% to $117.2 million in 2023, then slumped by 66.3% to $39.5 million in 2024, then slumped by 546.8% to -$176.6 million in 2025, then soared by 135.64% to $62.9 million in 2026.
- Business Quant data shows SLNO's Net Cash Flow at $62.9 million in Q1 2026, -$176.6 million in Q4 2025, and $170.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 62.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.92 Mn |
| Mar 31, 2026 | 62.92 Mn |
| Dec 31, 2025 | -176.55 Mn |
| Dec 31, 2025 | -176.55 Mn |
| Sep 30, 2025 | 170.21 Mn |
| Sep 30, 2025 | 170.21 Mn |
| Jun 30, 2025 | -4.87 Mn |
| Jun 30, 2025 | -4.87 Mn |
| Mar 31, 2025 | -6.60 Mn |
| Mar 31, 2025 | -6.60 Mn |
| Dec 31, 2024 | 39.52 Mn |
| Dec 31, 2024 | 39.52 Mn |
| Sep 30, 2024 | -8.61 Mn |
| Sep 30, 2024 | -8.61 Mn |
| Jun 30, 2024 | 14.18 Mn |
| Jun 30, 2024 | 14.18 Mn |
| Mar 31, 2024 | -126.83 Mn |
| Mar 31, 2024 | -126.83 Mn |
| Dec 31, 2023 | 117.24 Mn |
| Dec 31, 2023 | 117.24 Mn |